FLT3 and acute myeloid leukemia: Previous studies have found multiple mechanisms of HHT in treating AML, including targeting FLT3 pathway, antioxidant defense, SP1/TET1/5hmC pathway, TRAIL and p53 pathway, NF-κB pathway and the expression of myosin-9 and eIF4E (9–15).